Supplement for BNP Level Predicts Major Bleeding Events in Patients with Heart Failure After Percutaneous Coronary Intervention

Otsuka Y, et al.

CONTENTS

Supplementary Figure 1. Study flowchart of CLIDAS

Supplementary Figure 2. Study flowchart of T-TAS

Supplemental Figure 3. Kaplan–Meier estimates of bleeding events (GUSTO

severe/moderate) between the HF and non-HF groups


Supplemental Table.1 Baseline patient characteristics

Supplemental Table 2. Types of bleeding events during 3-year follow-up in patients with

and without HF

Supplementary Table 3. Types of bleeding events during 3-year follow-up according to


severity of HF



Supplemental Figure 1. Study flowchart of CLIDAS.


CLIDAS, Clinical Deep Data Accumulation System; PCI, percutaneous coronary

intervention; HF, heart failure; EF, ejection fraction



Supplemental Figure 2. Study flowchart of T-TAS

T-TAS, Total Thrombus-Formation Analysis System; HF, heart failure; BNP, B-type natriuretic peptide



Supplemental Figure 3. Kaplan–Meier estimates of bleeding events (GUSTO

severe/moderate) between the HF and non-HF groups

GUSTO, Global Use of Streptokinase and t-PA for Occluded Coronary Arteries; HF,

heart failure;

Supplemental Table.1 Baseline patient characteristics

	Patients without HF N = 6,645	Patients with HF N = 515	p-value	
Age	71 (64, 78)	75 (66, 80)	<0.001	
Male	5,183 (78%)	367 (71%)	<0.001	
BMI	23.9 (21.8, 26.3)	23.1 (20.6, 25.6)	<0.001	
SBP at discharge	118 (106, 130)	115 (100, 128)	<0.001	
DBP at discharge	64 (58, 72)	60 (54, 68)	<0.001	
PR at discharge	67 (60, 75)	70 (62, 78)	<0.001	
ACS	3,086 (46%)	143 (28%)	<0.001	
Hypertension	5,508 (83%)	457 (89%)	<0.001	
Dyslipidemia	5,224 (79%)	383 (74%)	0.02	
Diabetes	2,806 (42%)	294 (57%)	<0.001	
Smoking	1,367 (21%)	91 (18%)	0.24	
missing data	3,056 (46%)	241 (47%)	0.24	
CKD (eGFR <60)	2,917 (47%)	379 (76%)	<0.001	
missing data	417 (6%)	14 (3%)	10.001	
eGFR	62 (48, 74)	44 (21, 60)	<0.001	
Hemodialysis	372 (5.6%)	76 (15%)	<0.001	
Family_history_of_CVD	1,409 (21%)	92 (18%)	0.039	
missing data	1,279 (19%)	91 (18%)	0.039	
Malignancy	610 (9.6%)	62 (13%)	0.022	
Previous_MI	951 (14%)	143 (28%)	<0.001	
Previous_MI Previous PCI			<0.001	
Previous_PCI Previous CABG	1,322 (20%)	161 (31%)	<0.001	
	331 (5.0%)	82 (16%)		
Previous_Stroke Atrial_Fibrillation	759 (11%)	80 (16%)	0.005	
	272 (4.1%)	68 (13%)	<0.001 <0.001	
Peripheral_artery_disease Culprit lesion	518 (8.7%)	70 (15%)	\0.001	
RCA	3,386 (54%)	282 (59%)	0.034	
LAD	4,567 (73%)	360 (76%)	0.034	
LCX			0.003	
LMT	2,733 (44%)	242 (51%)		
	492 (7.9%)	52 (11%)	0.019	
missing data	415 (6.2%)	40 (7.8%)	0.002	
MVD	3,378 (51%)	299 (58%)	0.002	
BNP	51 (21, 134)	231 (98, 504)	<0.001	
HF with BNP over 100	0 (0%)	384 (75%)	<0.001	
EF	61 (51, 67)	45 (32, 56)	<0.001	
missing data	1,175 (18%)	43 (8.3%)	.0.001	
EF category	500 (0.50)	155 (200)	<0.001	
<40	532 (9.7%)	177 (38%)		
≧50	4,211 (77%)	186 (39%)		
40-49	727 (13%)	109 (23%)		
Anticoagulant	791 (12%)	144 (28%)	<0.001	
DOAC	308 (4.6%)	60 (12%)	< 0.001	
Warfarin	501 (7.5%)	87 (17%)	<0.001	
DAPT	5,683 (86%)	427 (83%)	0.11	
Aspirin	6,152 (93%)	471 (92%)	0.35	
P2Y12 inhibitor	6,047 (91%)	456 (89%)	0.063	
PPI	5,456 (82%)	425 (83%)	0.81	

Data are mean \pm SD, or n (%). Data for this parameter were measured at admission.

BMI indicates body mass index, SBP; systolic blood pressure, DBP; diastolic blood pressure, PR; pulse rate, ACS; acute coronary syndrome, CKD; chronic kidney disease, eGFR; estimated glomerular filtration rate, CVD; coronary vessel disease, MI, myocardial infarction, PCI; percutaneous coronary intervention, CABG; coronary artery bypass grafting RCA; right coronary artery, LAD; left anterior descending artery, LCX; left circumflex artery, LMT; left main trunk, MVD; multi vessel disease, BNP; B-type natriuretic peptide, EF; ejection fraction, DOAC; direct oral anticoagulants, DAPT; dual antiplatelet therapy, PPI; Proton pump inhibitor.

Supplemental Table 2. Types of bleeding events during 3-year follow-up in patients with

and without HF

	Non-HF	HF	p value
	N=6645	N=515	
Bleeding events	227 (3.4)	49 (9.5)	< 0.001
(GUSTO severe/moderate)			
ICH	53 (0.8)	12 (2.3)	0.002
GI bleeding	93 (1.4)	23 (4.5)	< 0.001
Puncture site	47 (0.7)	8 (1.6)	0.058
Trauma	2 (0.03)	0 (0)	>0.99
Other	32 (0.5)	6 (1.2)	0.052

HF indicates heart failure, ICH; intracerebral hemorrhage and GI; gastrointestinal.

Supplemental Table 3. Types of bleeding events during 3-year follow-up according to severity of HF

	Non-HF	HF with BNP ≤100	HF with BNP >100	p value for trend
	N=6645	N=131	N=384	
Bleeding events				
(GUSTO	227 (3.4)	9 (6.9)	40 (10.4)	< 0.001
severe/moderate)				
ICH	53 (0.8)	2 (1.5)	10 (2.6)	< 0.001
GI bleeding	93 (1.4)	4 (3.1)	19 (4.9)	< 0.001
Puncture site	47 (0.7)	2 (1.5)	6 (1.6)	0.039
Trauma	2 (0.1)	0 (0)	0 (0)	0.703
Other	32 (0.5)	1 (0.8)	5 (1.3)	0.03

HF indicates heart failure, BNP; B-type natriuretic peptide, ICH; intracerebral hemorrhage and GI; gastrointestinal.